Read More

AbbVie New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary And All Secondary Endpoints In An Open-Label Head-To-Head Atopic Dermatitis Study; Achieved Both A 90% Or Greater Reduction In Eczema Area And Severity Index And A Wors…

Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161LEVEL UP, a Phase 3b/4

ABBV

Read More

Compass Therapeutics Receives FDA Fast Track Designation For The Investigation Of CTX-009 In Combination With Paclitaxel For The Treatment Of Patients With Metastatic Or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

CTX-009, the Company's bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 studyTop-line data

CMPX